LEO 43204
Phase 2Small molecule
LEO PharmaLEO 43204 is one of 208 small molecule programs targeting Psoriasis Vulgaris. It is currently in Phase 2.
8
Indications
82
Total Trials
0
Active Trials
207
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1LEO 43204
LEO PharmaPhase 2
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis Vulgaris20 trials
Show 17 more trials
Actinic Keratosis9 trials
Show 6 more trials
Psoriasis9 trials
Show 6 more trials
Atopic Dermatitis8 trials
Show 5 more trials
Single Dose3 trials
20 more indications
Irritation3 trials
Trial3 trials
Vasoconstriction2 trials
TIA2 trials
Tics2 trials
Adult2 trials
Alopecia Areata2 trials
Ototoxicity1 trial
Interaction1 trial
Skin1 trial
Atrophy1 trial
Chronic Hand Eczema1 trial
Oral1 trial
Prospective1 trial
Immunogenicity1 trial
Renal Impairment1 trial
Secondary Hyperparathyroidism1 trial
Double-blind1 trial
Unspecified5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LEO 43204. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company